Use of thrombolytic therapy to treat heparin-refractory pulmonary embolism in a menstruating patient

Pharmacotherapy

Volumn 22, Issue 1, 2002, Pages 118-122

  Koch, Ada Z ^a   Abubaker, Jawed ^b   Barnett, V Theodore ^b   Chan, Lingtak Neander ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEMOGLOBIN; HEPARIN;

ADULT; ARTICLE; BLEEDING; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEMOGLOBIN DETERMINATION; HEPARINIZATION; HUMAN; LUNG EMBOLISM; MENSTRUATION; PATIENT MONITORING; RISK ASSESSMENT;

ADULT; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MENSTRUATION; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0036137963     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.1.118.33493     Document Type: Article

References (17)

1. Thrombolytic therapy for pulmonary embolism. A comprehensive review of current evidence
2. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on thrombosis (in consultation with the council on cardiovascular radiology)
3. Venous thromboembolism
4. The menstrual cycle
5. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry
6. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial
7. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism
8. Effect of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: A European multicenter double-blind trial
9. Thrombolytic therapy in thrombosis: A National Institutes of Health consensus development conference
10. Hemostasis in menstrual endometrium: A review
11. Is thrombolytic therapy safe during active menstruation?
12. Thrombolytic therapy for pulmonary embolism during menstruation
13. Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial
14. Thrombolytic therapy during active menstruation: A case report
15. Front-loaded infusion therapy of rT-PA during active menstruation. A case report
16. Is menstruation a contraindication to thrombolytic therapy?
17. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis